CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$5.7M
Cash & Equivalents
$1.3M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$9M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT06053242 Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba... PHASE2 Recruiting 45
NCT05626712 Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes PHASE2 Recruiting 18

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for CELZ.

SEC EDGAR Filings

All SEC filings for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.